Eleven research firms currently cover Encompass Health Corporation, yielding an average recommendation of Buy. Eight analysts have assigned Buy ratings, two have issued Strong Buy ratings and one has issued a Hold rating. The average 12-month target price among these analysts stands at $142.86. Notable recent upgrades include Raymond James Financial’s elevation to Strong Buy on October 31 and Barclays’ increase of its target from $141.00 to $150.00 alongside an Overweight rating on October 30. KeyCorp raised its target from $135.00 to $140.00 on September 16, while Wall Street Zen adjusted its view from Buy to Hold in early November.

In the third quarter ended September 30, Encompass Health reported revenue of $136.3 million and earnings per share of $0.93, reflecting a net margin of 9.33% and return on equity of 17.84%. The company maintains a quick ratio and current ratio both at 1.14, underscoring solid short-term liquidity, and carries a debt-to-equity ratio of 0.76. Over the past 52 weeks, shares have traded between $90.67 and $127.99, with the stock’s beta at 0.74. Institutional ownership remains high at 97.25%, indicating strong investor confidence.

Encompass Health announced a quarterly dividend of $0.19 per share, payable January 15 to shareholders of record as of January 2. This equates to an annualized payout of $0.76 and a dividend yield of approximately 0.7%. The company’s dividend payout ratio stands at 14.37%, reflecting conservative distribution relative to earnings and preserving capacity for reinvestment in hospital expansions and technology upgrades.

Encompass Health will report results for its fourth quarter ended December 31, 2025, after market close on February 5, 2026, with a conference call scheduled at 10 a.m. ET on February 6. Investors may dial into the call or access a live webcast via the company’s investor website. With 173 inpatient rehabilitation hospitals across 39 states and Puerto Rico, management is expected to discuss initiatives focused on expanding home health services and optimizing hospital utilization to drive full-year 2026 revenue and margin growth.